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Genetic susceptibility to multiple sclerosis (MS) is associated with the human leukocyte antigen (HLA)
DRB1*1501 allele. Here we show a clear association between DRB1*1501 carrier status and four domains of
disease severity in an investigation of genotype^phenotype associations in 505 robust, clinically well charac-
terized MS patients evaluated cross-sectionally: (i) a reduction in the N-acetyl-aspartate (NAA) concentration
within normal appearing white matter (NAWM) via
1HMR spectroscopy (P=0.025), (ii) an increase in the
volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques (1,127 mm
3; P=0.0 3 1 ) ,
(iii) a reduction in normalized brain parenchymal volume (nBPV) (P=0.023), and (iv) impairments in cogni-
tive function as measured by the Paced Auditory Serial AdditionT est (PASAT-3) performance (Mean Z Score:
DRB1*1501+: 0.110 versus DRB1*1501-: 0.048; P=0.004) .I nad d i t i o n,DRB1*1501+ patients had significantly more
women (74% versus 63%; P=0.009) and a younger mean age at disease onset (32.4 years versus 34.3 years;
P=0.025). Our findings suggest that DRB1*1501 increases disease severity in MS by facilitating the develop-
ment of more T2-foci, thereby increasing the potential for irreversible axonal compromise and subsequent
neuronal degeneration, as suggested by the reduction of NAA concentrations in NAWM, ultimately leading
to a decline in brain volume. These structural aberrations may explain the significant differences in cognitive
performance observed between DRB1*1501 groups. The overall goal of a deep phenotypic approach to MS is
to develop an array of meaningful biomarkers to monitor the course of the disease, predict future disease
behaviour, determine when treatment is necessary, and perhaps to more effectively recommend an available
therapeutic intervention.
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Introduction
The human leukocyte antigen (HLA) DRB1 1501-DQB1-
0602 haplotype is a well-established risk factor for multiple
sclerosis (MS) (Bertrams and Kuwert, 1972; Govaerts et al.,
1985; Barcellos et al., 2003; Oksenberg et al., 2004; Hafler
et al., 2007). Fine mapping data suggests that the DRB1
gene itself is responsible for a significant portion of this
risk (Ebers et al., 1996; Oksenberg et al., 2004). In Northern
European populations, more than half of individuals with
MS are DRB1 1501 positive, and even higher frequencies
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 are observed in some familial MS cohorts (Haines et al.,
1998; Rubio et al., 2002; Barcellos et al., 2006). Although
DRB1 1501 is the best studied susceptibility allele in MS,
the influence of the HLA region is complex (Haines et al.,
1998; Barcellos et al., 2002; Sawcer et al., 2005; Yeo et al.,
2007), and other DRB1 variants can also contribute to MS
risk, including DRB1 04 in Sardinians and Sicilians, and
DRB1 1503 and DRB1 03 in African-Americans (Marrosu
et al., 2002; Oksenberg et al., 2004; Brassat et al., 2005).
DRB1 1501 also influences MS susceptibility in a dose-
dependent fashion; homozygotes are at a several fold
higher risk compared with heterozygotes (Barcellos et al.,
2003). Although DRB1 alleles clearly influence MS sus-
ceptibility, little is known about whether HLA variation
influences clinical manifestations or outcomes in MS
(Kantarci et al., 2002; Villoslada et al., 2002).
The current study was stimulated by our previous
analysis of the Optic Neuritis Treatment Trial (ONTT)
group, in which we reported that individuals carrying the
DRB1 1501 allele exhibited higher numbers of focal brain
lesions at the time of initial presentation with optic neu-
ritis (Hauser et al., 2000). This observation suggested that
DRB1 genes might influence the radiological characteris-
tics of MS patients at an early time point in their disease
course. In the present study, we utilized a large, clinically
well-characterized group of MS patients to further explore
the relationship between neuroimaging parameters and
DRB1 1501 carrier status. In addition to conventional
anatomic MR end-points, we utilized an advanced pro-
ton spectroscopic metabolic imaging metric as a marker
of neuronal integrity in regions of normal appearing
white matter (NAWM), which have been reported to be
significantly abnormal in MS compared to normal con-
trols (Fu et al., 1998; Oh et al., 2004; Srinivasan et al.,
2005), along with a fully automated, validated technique
utilized in the assessment of normalized brain volume
(Smith et al., 2001, 2007). The results of this analysis led
us to test the hypothesis that there may be a clinical
correlation with regard to cognitive performance and the
radiological differences observed between patients who
carry DRB1 1501 versus those that do not. Thus, we also
report an association between the HLA-DRB1 1501 gene
and cognitive function.
Methods
Research participants
The population was ascertained through a prospective study of
phenotype–genotype-biomarker associations in a large cohort of
MS patients followed longitudinally. Patients (aged 18–65 years)
evaluated at the Multiple Sclerosis Center at the University
of California, San Francisco (UCSF) between July 2004 and
September 2005 were invited to participate. Patients with a recent
onset of MS were preferentially recruited, although individuals
with all clinical subtypes of the disease participated. These dis-
ease types included: clinically isolated syndrome (CIS), relaps-
ing remitting MS (RRMS), secondary progressive MS (SPMS),
primary progressive MS (PPMS), and progressive relapsing MS
(PRMS). Patients were not entered if they had experienced a
clinical relapse or received treatment with glucocorticosteroids
within the previous month. The concomitant use of disease
modifying therapies for MS was permitted. The protocol was
approved by the Committee on Human Research at UCSF, and
informed consent was obtained from all participants.
HLA-DRB1 1501 typing
HLA-DRB1 genotypes were determined using a validated allele-
specific TaqMan probe-based, 50 nuclease assay specific for
DRB1 1501. High quality genomic DNA for all samples, includ-
ing positive and negative controls, were organized, and 2ml were
aliquoted into 384 well plates for PCR amplification. An internal
positive control (b-globin) was included in each well to confirm
successful amplification of the reaction. PCR was carried out in
a total volume of 10ml, containing 20ng DNA, 1 TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster City,
California), 0.6mM DRB1 1501 specific primers, 0.3mM control
primers, 0.225mM VIC-labeled DRB1 1501 probe, and 0.025mM
6FAM-labeled control probe. Amplification was carried out in
an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) with an initial 95 C cycle for 10min, followed by
50 cycles of 95 C for 15s and 62
 
C for 1min. Samples were
considered to contain at least one copy of the DRB1 1501 allele
if the respective cycle exceeded a pre-established threshold.
Image acquisition
Brain MRI scans were performed on all subjects upon entry
into the study, and analyses were carried out without knowledge
of disease subtype, duration or treatment history. MRI images
were acquired using an 8-channel phased array coil in recep-
tion and a body coil in transmission on a 3T GE Excite
scanner (GE Healthcare Technologies, Waukesha, WI). Each MR
imaging examination included scout localizers and axial dual-
echo spin echo sequences (TE at 20 and 90ms, TR=2000ms,
512 512 44 matrix, 240 240 132mm
3 FOV, slice thick-
ness=3mm, interleaved). A high-resolution inversion recovery
spoiled gradient-echo T1-weighted isotropic, volumetric sequence
(3D IRSPGR, 1 1 1mm
3, 180 slices) was also performed
(TE/TR/TI=2/7/400ms, flip angle=15 , 256 256 180 matrix,
240 240 180mm
3 FOV, NEX=1). Conventional spin echo,
T1-weighted images were acquired 5min following administration
of a single dose (0.1mM/kg) of contrast agent (TE/TR=8/467ms,
256 256 44 matrix, 240 240 132 FOV, NEX=1).
Brain lesions were identified by medical doctors (M.D.)
specializing in MS (DTO, AB) on simultaneously viewed
high-resolution T1-weighted, T2-weighted, and proton density-
weighted images. Regions of interest (ROI) were drawn based
on a semi-automated threshold with manual editing utilizing
in-house software, and T1-lesion masks created; the process
described elsewhere (Blum et al., 2002). Both intra and inter-
observer variability analyses were performed to ensure the accu-
racy of data acquired. T2-lesion volumes from ROI selections
were calculated by multiplying the area of the lesion by the
slice thickness and the number of slices penetrated using
in-house software. A qualitative analysis for the presence of
gadolinium enhancement was performed on post-contrast
T1-weighted images.
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 Brain tissue segmentation and normalization
Brain segmentation and normalization was performed using
SIENAX (Image Analysis Group, Oxford, UK), a fully automated
technique. T1-lesion masks (described above) were presented
to the SIENAX programme to correct for misclassifications of
parenchymal tissue while T1-weighted images were segmented
into images representing the volume of each voxel containing
grey matter (GM), WM, cerebral spinal fluid (CSF), and WM
lesion. The lesion masks overrode all SIENAX tissue classifica-
tions. Normalized tissue volumes were calculated by summing
the lesion corrected, partial volume estimate maps, multiplied
by the brain scalling factor calculated by the SIENAX programme
yielding the normalized brain parenchymal volume (nBPV).
Spectral acquisition and quantification
TE-Averaged MRSI spectra were acquired with an in-plane
resolution of 1.2 1.0cm over a single slice of thickness 1.5cm
in the supra-tentorial brain just above the corpus callosum
(Srinivasan et al., 2006). The spectroscopic data were acquired on
a 3T GE Excite scanner (GE Healthcare Technologies, Waukesha,
WI) using an 8-channel phased coil immediately following the
acquisition of the anatomical images and prior to the adminis-
tration of the contrast agent. The resulting coil combination data
were TE-averaged and the metabolic concentration of N-acetyl-
aspartate (NAA) were obtained using an LCmodel quantification
algorithm and corrected for T1 and T2 relaxation times using
similar methods described elsewhere (Ratiney et al., 2007). Only
metabolite estimates within 5% Cramer-Rao error estimates were
included in the analysis.
Parameter estimates in ‘Pure’ grey and
white matter
Non-brain regions were removed from the anatomical images
using a semi-automated brain extraction tool. T1-weighted images
were segmented into GM, WM, and CSF compartments using a
hidden Markov random field model with expectation maximiza-
tion (Zhang et al., 2001). The GM and WM maps were re-grid to
the spectroscopic resolution and convolved with the point spread
function for spectroscopic imaging to yield the percent GM and
WM content within each spectroscopic voxel. By modelling the
NAA concentrations and MR relaxation parameters as a linear
function of WM content, ‘pure’ GM and WM NAA concentra-
tions were extrapolated from the end-points of the linear fit
(Hetherington et al., 1996; Noworolski et al., 1999).
Clinical measures
For all subjects, the Expanded Disability Status Scale (EDSS)
(Kurtzke et al., 1983), Multiple Sclerosis Functional Composite
(MSFC) (Fischer et al., 1999), Functional Assessment in MS
(FAMS), and brain MR scans (described above) were performed
within 2 weeks of entry into the study. CIS was defined as
the first well-defined neurological event lasting 548h, involv-
ing the optic nerve, spinal cord, brainstem, or cerebellum. In CIS
patients, the presence of two or more hyperintense lesions on a
T2-weighted MRI sequence was also required for enrollment into
the study. The diagnosis of RRMS was made utilizing the new
International Panel criteria (McDonald et al., 2001; Polman et al.,
2005). SPMS was defined by 6 months of worsening neurological
disability not explained by clinical relapse; deterioration was
measured as either: (i) an increase of one or more points on
the EDSS in patients with scores 56.0, or (ii) an increase of
one-half point or more for those with EDSS scores 56.0.
PPMS was defined both by (1) progressive clinical worsening
for 412 months from symptom onset without any relapses,
and (2) abnormal cerebrospinal fluid (CSF) as defined by the
presence of 52 oligoclonal bands or an elevated IgG index.
If acute relapses were superimposed on this steadily progressive
course, patients were considered to have PRMS.
MS functional composite protocol
Three formally trained research coordinators at the UCSF MS
Center administered the MSFC. Formal didactic descriptions and
a standardized protocol for administering the MSFC were uti-
lized for all patients. All examiners were blinded to MS subtype,
DRB1 1501 status, and radiological outcomes. Instructions were
provided in English only. Testing order included: (i) 9-Hole Peg
Test (9-HPT) (two timed trials of the dominant hand performed
in succession followed by the assessment of the non-dominant
hand), (ii) Paced Auditory Serial Addition Test (PASAT-3) (single
trial with 3-s inter-stimulus intervals) and (iii) 25-Foot Timed
Walk (25-FTW) (two-timed trials). Attempts were made to ensure
that the same MSFC examiner performed all studies longitudinally
for a given patient.
A single version of the PASAT (PASAT-3A), with score range
from 0 to 60, was used. Directions were formally read to the
patient and one to three practice runs of 11 pre-selected numbers
with 10 possible responses provided prior to scoring. The test was
aborted if patients were unable to provide at least two non-
consecutive correct answers during the practice session. The test
was also aborted, and number of correct responses determined,
if a request was made during the evaluation for the test to be
terminated.
MSFC scores were derived by the methods previously des-
cribed by the National MS Society’s Clinical Assessment Task
Force (Fischer et al., 1999). Standardized scores (Z-scores) were
calculated for the 9-HPT, PASAT-3, and 25-FTW representing
the number of standard deviation units of performance from
the reference population (entire MS cohort) mean. Z-Scores for
the 9-HPT were calculated by averaging the two trial times for
each hand followed by conversion to an averaged reciprocal time.
The reciprocal mean performance time for the reference pop-
ulation was subtracted from the individual patient’s averaged
reciprocal time then divided by the reference population standard
deviation. Z-scores for the 25-FTW were calculated by subtracting
the average time from the reference population from the average
of the two-timed 25-FTW trials then divided by the reference
population standard deviation. PASAT-3 performance was calcu-
lated by determining the number of correct responses during a
single trial using a 3-s stimulus interval. Z-scores were calculated
by determining the difference between the patient’s performance
and reference population mean then divided by the reference
population standard deviation.
The MSFC score was derived by the following equation:
MSFC Score ¼½ðZ-score 1=9-HPTÞþð   Z-score 25-FTWÞ
þð Z-score PASAT-3Þ =3
Positive Z-scores represent the number of standard deviation units
of performance better than the reference population mean.
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 FAMS
Self-Reported Questionnaires [FAMS (Version 4)] focusing on:
(i) emotional well-being; (ii) thinking and fatigue, and (iii) pain
were administered at baseline. Patients were advised to provide
assessments based on their experience over the past 7 days. Scores
ranging from 0 (not at all) to 4 (very much) were assigned to the
emotional well-being (seven questions) and thinking and fatigue
(nine questions) sections. A Pain Intensity Numerical Rating Scale
ranging from 0 (no pain) to 10 (worst possible pain) was used to
assess pain intensity associated with MS or MS treatments over the
previous 12 months.
Statistical analysis
The frequency of DRB1 1501 was compared against gender,
disease subtype, age of disease onset, disease duration, presence
or absence of treatment, EDSS, T2-lesion volumes and gadolin-
ium enhancement. Box–Cox transformation was performed on
T2-lesion volumes prior to analysis for the treatment of non-
normality (Box and Cox, 1964). Kolmogorov-Smirnov test for
normality was performed on the transformed T2-lesion volumes
and NAA concentrations. Analysis of Covariance (ANCOVA) was
used to assess for differences in the transformed T2-lesion vol-
umes between DRB1 1501 haplotypes. The differences between
the adjusted mean values [least-squares means (LSMeans)] of
the transformed T2-lesion volumes and NAA concentrations
between haplotypes were compared using a Student’s T-test.
Multi-colinearity among the variables in the model was exam-
ined by assessing the tolerance. Linear regression analysis was
used to study the association between DRB1 1501 carriers and
NAA concentrations, Box–Cox transformed T2-lesion volumes,
and nBPV measurements with relevant confounding variables
incorporated in the model.
For the non-parametric analysis, the untransformed T2-lesion
volumes were divided into quartiles from Q1 to Q4; with Q1
representing lowest lesion volumes and Q4 containing the highest
lesion load. Logistic regression was used to assess the likelihood
of DRB1 1501 patients falling into the higher quartiles compared
to non-carriers. Data from Q1 was used as the reference category
for calculating the odds ratios (ORs) and degree of significance
(P-values). Potential confounding variables were included in the
model.
A Wilcoxon Two-sample test was performed comparing base-
line EDSS and FAMS scores in addition to 9-HPT, PASAT-3, and
25-FTW Z-scores along with overall MSFC performance between
DRB1 1501+ and DRB1 1501- MS patients. A generalized linear
model (SAS v.9.1.3 GENMOD Procedure) was utilized, incor-
porating the maximum likelihood estimation for regression
coefficients for important covariates in the model (age, age of
disease onset, disease duration, prior exposure to immunotherapy,
T2-lesion volumes, and baseline PASAT Z-scores) and likelihood
ratio test to examine the DRB1 1501 effect. Multi-colinearity
among the variables in the model was examined by assessing
tolerance.
All statistical analyses were performed using SAS v.9.1.3
(SAS Institute Inc., North Carolina, USA). A P-value40.05
was considered statistically significant.
Results
A total of 511 patients were enrolled during the study
period. Six patients were excluded due to motion artifact
on the MRI scan (n=2) or lack of the appropriate MR
dual-echo sequence performed for lesion volume determi-
nation (n=4). Of the 505 cases available, the specific MS
subtypes included: 88 CIS, 352 RRMS, 46 SPMS, 14 PPMS,
three PRMS, and two patients with an uncertain MS
subtype. Table 1 summarizes the clinical data for the entire
cohort. The distribution of the clinical and demographic
data divided on the basis of DRB1 1501 haplotypes (either
positive or negative) is shown in Table 2. The DRB1 1501+
group had significantly more women (74% versus 63%;
P=0.009) and a younger mean age at disease onset
(32.4 years versus 34.3 years; P=0.025) compared to the
DRB1 1501- group.
Spectroscopic metabolic data were acquired from 409
patients (1501+: 185, 1501-: 224) of the 505 cases available
(81%). Table 3 summarizes the demographic and clinical
data for these patients. A significantly lower concentration
of NAA in the NAWM was observed in the DRB1 1501+
group (P=0.025), with similar mean concentrations of
NAA identified in NAGM (P=0.221). Linear regression
Table 1 Summary of the demographic and clinical data for the entire study cohort
N Mean Median Range
Age (Y) 503 42.1 42.0 17^65
Gender 505 F: 344(68%); M: 161(32%)
Age of disease onset (Y) 503 33.5 33.0 1 1^60
Disease duration (Y) 503 9.68 7 .00 1.0^46.0
MS treatment exposure 505 YES: 348(69%); NO:157(31%)
HLA-DRB1*1501 505 1501+: 232(46%); 1501-: 273(54%)
EDSS score 505 2.0 1.5 0.0^7 .0
N-Acetyl-Aspartate ^ NAWM (mM) 409 9.96 9.89 6.86^14.47
MSFC score 487 0.051 0.208  4.920^1.186
T2-Lesion load (mm
3) 503 7365.2 3082.3 0.0^87641.0
Normalized brain parenchymal volume (cm
3) 504 1588.8 1600.9 1270.0^1821.9
Y=years; F=female; M=male; EDSS=expanded disability status scale; NAWM=normal appearing white matter; MSFC=multiple
sclerosis functional composite.
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 analysis incorporating significant covariates (e.g. gender,
age of disease onset, T2-lesion volume, and disease
duration) on the effect of NAA concentration in NAWM
continued to demonstrate a statistically significant
concentration reduction in the DRB1 1501+ group
(P50.05).
Using ANCOVA, a greater value of the transformed
and adjusted T2-lesion volume, consistent with a higher
Table 2 Summary of demographic and clinical data by HLA-DRB1*1501haplotype
HLA-DRB1*1501 Mean SD Median P-value
Age (Y) 1501+ 41.4 9.9 41 0.116
1501  42.7 9.8 43
Gender 1501+ F: 171(74%); M: 60 (26%) 0.009
1501  F:173(63%); M:101(37%)
Age of disease onset (Y) 1501+ 32.4 8.8 32 0.025
1501  34.3 9.7 34
Disease duration (Y) 1501+ 9.99 8.5 7 .0 0.170
1501  9.41 9.2 6.0
MS treatment exposure 1501+ YES:163(71%); NO: 68(29%) 0.462
1501  YES:185(68%); NO: 89(32%)
HLA-DRB1*1501 1501+ 232 (46%) 0.609
1501  273 (54%)
EDSS score 1501+ 1.9 1.6 1.5 0.201
1501  2.1 1.7 2.0
MSFC score 1501+ 0.082 0.631 0.197 0.434
1501  0.034 0.710 0.223
9-Hole peg test
a 1501+ 0.003 0.958 0.116 0.738
1501  0.017 1.027 0.097
PASAT-3
a 1501+ 0.110 1.070  0.128 0.004
1501  0.048 0.935 0.266
25-FTW
a 1501+ 0.017 0.789  0.0001 0.1 19
1501  0.120 1.149 0.0329
T2-Lesion load (mm
3) 1501+ 8109.8 13006 3337.1 0.031
1501  6786.2 10137 2828.5
Normalized brain 1501+ 1585.9 90.3 1589.6 0.023
parenchymal volume (cm
3)1 5 0 1   1591.4 88.6 1607.6
Volume scaling factor 1501+ 1.33 0.11 1.33 0.600
1501  1.34 0.12 1.33
aZ Score.Y=years; F=female; M=male; EDSS=expanded disability status scale; MSFC=multiple sclerosis functional composite;
PASAT=paced auditory serial addition test; 25-FTW=25-Foot timed walk.
Table 3 Summary of the demographic and clinical data for patients undergoing
1HMR analysis
N Mean SD Median Range
Age (Y) 409 43.9 9.8 43.5 18.0^66.9
Gender 409 F: 274(67%); M:135(33%)
Age of disease onset (Y) 409 33.6 9.4 33.0 1 1.0^59.0
Disease duration (Y) 409 10.0 9.0 7 .1 0.0^46.0
MS treatment exposure 409 YES: 282(69%); NO:127(31%)
HLA-DRB1*1501 409 1501+:185(45%); 1501 : 224(55%)
EDSS score 409 2.3 1.7 2.0 0.0^7.0
N-Acetyl-Aspartate ^ NAWM (mM) 409 9.96 1.28 9.89 6.86^14.47
1501+ (N=1 85) P=0.025 9.80 1.30 9.70 6.86^14.47
1501  (N= 224) 10.10 1.30 10.10 7.12^13.67
T2-Lesion load (mm
3) 409 7211.2 10972.9 3151.5 0.0^86610.3
Y=years; F=female; M=male; EDSS=expanded disability status scale; NAWM=normal appearing white matter.
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 burden of disease, was found for the DRB1 1501+ group
(see Methods for details of this analysis). Back transforma-
tion of the adjusted means showed a 1,127mm
3 greater
lesion volume in the DRB1 1501 group compared to all
other DRB1 alleles (P=0.031).
Non-parametric statistical methods were used to com-
pare the quartiles for untransformed T2-lesion volumes
and to confirm the results obtained from the parametric
statistical analysis. Gender (P=0.652) and HLA-DRB1 1501
status (P=0.066) were not associated with T2-lesion
volume (Table 4). By contrast, age (P=0.030), age at
disease onset (P50.0001), disease duration (P50.0001),
previous exposure to immunotherapy (P50.0001) and
EDSS (P50.0001) were associated with greater T2-lesion
volumes. DRB1 1501+ subjects classified with CIS, RRMS,
and SPMS were 1.90 times (P=0.015) more likely to have
higher T2-lesion volumes with values falling into Q2 versus
Q1 and 1.69 times more likely to fall into Q3 versus
Q1 (P=0.049) when age of disease onset, duration of
disease, and DRB1 1501 status were included as predictors.
Significant differences were not observed in the ORs when
comparing Q4 versus Q1 (P=0.314). Logistic regression did
not reveal substantial differences in the ORs or statistical
significance with the addition of potentially confounding
covariates (Table 5). Inclusion of the PPMS and PRMS
subtypes revealed similar ORs and degrees of significance
between quartiles (data not shown).
Linear regression analysis, incorporating significant
covariates (i.e. age of disease onset, gender, duration of
disease, EDSS, and exposure to treatment), revealed a
significant reduction in nBPV for the DRB1 1501+ group
with a least squares mean difference of 14cm
3 (P=0.023)
observed, representing a 0.9% reduction in the total brain
volume between DRB1 1501 carriers and non-carriers. No
significant difference was observed in the normalized
scalling factors for both groups.
Analysis of the impact of DRB1 1501 on cognitive
function revealed a statistically significant difference
in PASAT-3 performance between haplotypic groups
(P=0.004), a result that remained significant after a
Table 4 Summary of the demographic and clinical data byT2-lesion load quartiles
Q1 Q2 Q3 Q4
T2-Lesion load (mm
3) N=1 26 N=1 26 N=1 26 N=1 25
Mean=335.07 Mean=1889.45 Mean=5336.18 Mean=22016.27
SD = 254.38 SD = 631.06 SD = 1527.66 SD = 15222.37
Median=297 .62 Median=1882.95 Median=5121.50 Median=16386.55
Range: 0^887 .92 Range: 915.60^3082.32 Range: 3119.24^8738.09 Range: 8864.65^87641.24
Age (Y) N=1 25 N=1 25 N=1 26 N=1 25
P=0 . 030 Mean=39 . 9 Mean=4 1 . 9 Mean=42.8 Mean=43 .7
SD = 9.1 SD = 9.6 SD = 9.7 SD = 10.8
Median=40.0 Median=42.0 Median=41.5 Median=43.0
Range: 17^65 Range: 18^64 Range: 23^63 Range: 19^65
Gender F: 87 (25.5%) F: 87 (25.5%) F: 88 (25.8%) F: 79 (23.2%)
P=0.652 M: 39 (24.1%) M: 39 (24.0%) M: 38 (23.5%) M: 46 (28.4%)
Age at disease onset (Y) N=1 25 N=1 25 N=1 26 N=1 25
P50.0001 Mean=34.5 Mean=35.2 Mean=33.6 Mean=30.3
SD = 8.6 SD = 8.6 SD = 9.7 SD = 9.4
Median=35.0 Median=35.0 Median=32.0 Median=29.7
Range: 13^55 Range: 17^58 Range: 17^60 Range: 11^58
Disease duration (Y) N=1 25 N=1 25 N=1 26 N=1 25
P50.0001 Mean=6.5 Mean=7 .7 Mean=10.2 Mean=14.4
SD = 6.5 SD = 7.1 SD = 8.6 SD = 10.7
Median=4.0 Median=5.0 Median=7 .0 Median=12.0
Range: 1^35 Range: 1^38 Range: 1^37 Range: 1^46
MS treatment exposure NO: 59 (47 .2%) NO: 36 (28.8%) NO: 34 (27.0%) NO: 27 (21.6%)
P50.0001 YES: 66 (52.8%) YES: 89 (71.2%) YES: 92 (73.0%) YES: 98 (78.4%)
HLA-DRB1*1501 1501+: 45 (19.7%) 1501+: 64 (28.0%) 1501+: 62 (27.2%) 1501+: 57 (25.0%)
P=0 . 066 1 50 1 :8 0( 2 9 . 4 % ) 1 5 0 1  :6 1( 2 2 . 4 % ) 1 5 0 1  :6 2( 2 2 . 8 % ) 1 5 0 1  :6 9( 2 5 . 4 % )
EDSS score N=1 25 N=1 25 N=1 26 N=1 25
P50.0001 Mean=1.58 Mean=1.77 Mean=1.97 Mean=2.72
SD = 1.50 SD = 1.46 SD = 1.43 SD = 1.93
Median=1.5 Median=1.5 Median=1.5 Median=2.0
Range: 0^7 Range: 0^6 Range: 0^6 Range: 0^7
Y=years; F=female; M=male; EDSS=expanded disability status scale.
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 sensitivity analysis for potential confounders (P50.005).
Patient age, disease duration, EDSS, FAMS, and MSFC
scores, along with exposure to immunotherapy, the type of
such therapy, and the presence of gadolinium enhancing
lesions were similar between groups.
Discussion
An effect of the HLA-DRB1 1501 gene on four domains
of disease severity in MS was identified: (i) a reduction in
NAA concentration within NAWM by MR spectroscopy
suggesting alterations in neuronal integrity not discernable
through conventional techniques, (ii) a higher adjusted
mean T2-lesion volume utilizing conventional MR mea-
sures, (iii) reduced normalized brain volume utilizing high-
resolution images, and (iv) impairments in cognitive
function as measured by PASAT-3 performance. Taken
together, these data, derived from a large and prospectively
ascertained population, indicate that DRB1 1501 increases
disease severity in MS by facilitating the development of
more T2-foci, which has the potential of transecting axons,
leading to widespread axonal compromise (reduction of
NAA in NAWM) and subsequent degeneration with resul-
tant brain atrophy and associated injury suggested by the
presence of cognitive impairment (decline in PASAT-3
performance).
Disease-modifying therapies for MS, used by many
patients in the cohort, were unlikely to have influenced
the outcomes reported here. The proportion of patients
treated with interferon (IFN), glatiramer acetate (GA), or
immune suppression was similar between the DRB1 1501+
and DRB1 1501- groups, as was the total duration of
treatment. One earlier unconfirmed study with limited
power suggested the presence of an interaction between
DRB1 1501 and a treatment response to GA (Fusco
et al., 2001). However, this effect, if present, would have
biased results in the opposite direction to those observed
here (i.e. GA treated DRB1 1501+ patients would have been
expected to accumulate fewer focal MS lesions). We pre-
viously reported, in a different population of MS patients,
that responses to IFN are not influenced by DR status
(Villoslada et al., 2002). Interestingly, the influence of
DRB1 1501 on T2-lesion volume appeared to decrease
as the total burden of disease increased. With increasing
T2-lesion volume there is less remaining normal WM at
risk for demyelination, which could slow the accumula-
tion of new focal lesions and blunt any inter-group
differences.
The metabolite N-acetyl-aspartic acid is principally
viewed as a marker of neural integrity, because of its high
concentration in neurons, dendrites, axons, and synapses
in the CNS (Birken and Oldendorf, 1989; Simmons et al.,
1991). NAA concentrations are known to be reduced in
chronic MS lesions (van Walderveen et al., 1999), a finding
interpreted as neuronal or axonal loss, although questions
remain unanswered with regard to the dynamic nature
of NAA changes and their reversibility or irreversibility
(Oh et al., 2004). Previous studies of NAA in NAWM
employed single-voxel MRS techniques that have lower
spatial resolution than the 2D multi-voxel modality used
in this study, precluding firm associations from being
identified. In an earlier study of NAWM in the corpus
callosum of MS patients, we reported reduced NAA values
(Oh et al., 2004). In RRMS and SPMS, these MR outcomes
were strongly influenced by the presence of distant peri-
callosal MS lesions, consistent with a secondary degen-
erative process (i.e. Wallerian degeneration) occurring in
normal appearing brain regions. The difference observed
here in NAA concentrations suggest that a reduction in
axonal density or integrity is associated with the presence
Table 5 Logistic regression analysis and effect of potential confounders onT2-lesion load volume
Logistic regression equation R
2 Q2/Q1
Odds ratio
95% CI
Q3/Q1
Odds ratio
95% CI
Q4/Q1
Odds ratio
95% CI
RR/SP/CIS (N=483) T2LL=AODO+DD+DRB1*1501 0.15 1.90 1.69 1.32
P=0.0 1 5 P=0.049 P=0 .3 1 4
1.13^3.20 1.00^2.86 0.77^2.29
RR/SP/CIS (N=483) T2LL=AODO+DD+EDSS+DRB1*1501 0.18 1.92 1.74 1.38
P=0.0 1 4 P=0.039 P=0.258
1.14^3.23 1.03^2.94 0.79^2.40
RR/SP/CIS (N=482) T2LL=AODO+TX+DD+DRB1*1501 0.19 1.97 1.76 1.39
P=0.0 1 2 P=0.038 P=0 .2 45
1.16^3.33 1.03^3.00 0.80^2.43
RR/SP/CIS (N=482) T2LL=A O DO+TX+D D+EDSS+DRB1*1501 0.21 1.97 1.79 1.4 4
P=0.0 1 2 P=0.032 P=0 .2 1 0
1.16^3.35 1.05^3.06 0.82^2.52
RR=relapsing-remitting MS; SP=secondary-progressive MS; CIS=clinically isolated syndrome;T2LL=T2-lesion load; AODO=age of
disease onset; DD=disease duration;TX=exposure to MS treatment.
Significance of bold values is P40.05.
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 of DRB1 1501. Longitudinal studies are in progress, and
these should better define the evolution of spectroscopic
metabolite concentrations in normal appearing brain
regions, especially as patients transition from the relapsing
to the progressive stage of MS.
Cognitive impairment in MS is a common cause of
clinical disability in MS, and a symptom that exhibits
discordant features with the degree of motor impairment
(Piras et al., 2003). That DRB1 1501 patients have a higher
T2 burden of disease and reduced brain parenchymal
volume suggested the possibility of a difference in cogni-
tive impairment in DRB1 1501 patients compared to other
DRB1 alleles. T2-lesion volume and brain atrophy were
previously correlated with the evolution of cognitive decline
in MS (Rao et al., 1989, 1991; Piras et al., 2003; Houtchens
et al., 2007). The presence of T2-foci is directly associated
with irreversible axonal transection and compromise
(Trapp et al., 1998); thereby providing an explanation for
previous studies demonstrating the association between
burden of disease and cognitive integrity. Compromises in
cognitive function, signified by PASAT-3 performance, may
also be related to subsequent secondary degeneration, as
observed in our dataset with significant changes noted
between DRB1 1501 groups and brain volumes normalized
for intracranial skull size. Investigations correlating both
semi and fully automated whole brain volumetric tech-
niques to cognitive performance in MS are nascent and
definitive data controlling for important covariates are
deficient. More recently, NAA concentration and executive
function in healthy individuals were also correlated, sug-
gesting alterations in brain integrity not appreciated with
conventional techniques (Charlton et al., 2007). Efforts
were made in this study to ensure that fatigue and mood
disorders were not potential contributors to a decline in
PASAT-3 performance. The lack of statistical differences
in self-reported FAMS scores suggests that these were
not significant contributing factors. It is likely that the
correlations between NAA, T2-lesion volume, nBPV and
PASAT-3 observed here provide overlapping evidence
for an association between HLA-DRB1 1501 and MS
severity (Fig. 1).
The gene products of DRB1 1501 in white popula-
tions, and the closely related DRB1 1503 in blacks, share
in common a structurally related hydrophobic peptide-
binding motif facilitating tight binding to aromatic amino
acids that includes the critical aa92 (Phe) residue of the
89–96 region of myelin basic protein (MBP). This peptide
sequence is known to be immunodominant in DRB1 1501
individuals, resulting in efficient presentation of MBP
89–96, or a related cross-reactive (possibly viral) peptide,
to T cells (Ota et al., 1990; Wucherpfennig et al., 1994,
1995), specific activation of T cells in the circulation of
DRB1 1501 individuals with MS (Allegretta et al., 1990;
Scholz et al., 1998), and the presence of 89–96 MBP reac-
tive T cells in MS plaques (Oksenberg et al., 1993). By
analogy to animal models of T cell mediated autoimmune
demyelination (Zamvil et al., 1985), early in the disease
course focal lesions may result from a relatively limited
number of pathogenic T cell specificities. Over time,
epitope spreading may occur, increasing the number of
autoantigen targets recognized by pathogenic T cells and
the diversity of HLA restricting elements mediating the
disease. We would speculate that, in DRB1 1501+ indi-
viduals with MS, high numbers of MBP-reactive T cells
stochastically favour the development of more focal lesions
early in the disease course, and also greater concentration
of encephalitogenic T cells in lesions favouring secondary
axonal degeneration measured as loss of NAA in NAWM.
Continued intra- and inter-molecular epitope spreading,
as well as the development of pathogenic T cell responses
not restricted to DRB1 1501, could modulate this effect of
DRB1 1501 over time. This biologically plausible mecha-
nism, in addition to the lack of neurodegeneration observed
without inflammation in animal models (Lorentzen et al.,
1995; Zhou et al., 2006), supports our rationale of a
mechanistic cascade of disease severity.
In summary, these results demonstrate a robust associa-
tion between the DRB1 1501 haplotype and MS disease
severity. An association between DRB1 1501 and disease
severity, as measured by spectroscopic metabolic differ-
ences, with a reduction in the concentration of NAA in
NAWM was observed; the result of an increased burden of
disease observed on conventional anatomic imaging as well
as disease in NAWM not yet discernable utilizing conven-
tional MRI techniques. These imaging findings, along with
alterations in nBPV between groups, are likely respon-
sible for the alterations in cognitive integrity observed.
Longitudinal studies—combining imaging, genetic, and
clinical variables, in addition to other biomarkers are
currently underway to test and extend these cross-sectional
findings. These technologies offer a remarkable opportunity
to investigate heterogeneity in MS. In another example, we
Fig. 1 Schematic representation of the relationship between
MS and disease severity with the influence of confounders, in
addition to the effect modifier, HLA-DRB1  1501, that is proposed
to facilitate increased brain injury. A unidirectional arrow indi-
cates a causal association. A non-causal relationship is indicated
by the bidirectional arrow.
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 have recently reported that expression profiling of CD4 cells
can robustly predict the future behaviour of CIS patients
for period of 1 year (Corvol et al., 2008). The overall goal
of a deep phenotypic approach to MS is to develop an
array of meaningful biomarkers to monitor the course of
the disease, predict its future behaviour, determine when
treatment is necessary, and perhaps also select from among
available therapies. Longitudinal studies, combining imag-
ing, genetic, and clinical outcomes, in addition to other
biomarkers, are currently underway to affirm and extend
these novel data. Similar studies and results from inde-
pendent datasets would also provide additional confirma-
tion. Overall, these efforts are likely to substantially clarify
the underlying biology of MS.
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